Valeritas’ V-Go® Disposable Insulin Delivery Device Demonstrated Greater Glycemic Control, Less Insulin Utilization and Cost Effectiveness when Compared to Subcutaneous Multiple Daily Insulin Injections

BRIDGEWATER, New Jersey, February 16, 2016 – Valeritas Inc. announced today the rapid access online publication last week of a retrospective study analysis titled “Clinical and Cost Effectiveness of Insulin Delivery with V-Go® Disposable Insulin Delivery Device versus Multiple Daily Injections in Patients with Type 2 Diabetes Inadequately Controlled on Basal Insulin” in Endocrine Practice, the official peer-reviewed journal of the American Association of Clinical Endocrinologists (AACE).

For more information, click here.